Advanced search
Publication Cover
International Medical Case Reports Journal Volume 16, 2023 - Issue
Submit an article Journal homepage
288
Views
1
CrossRef citations to date
0
Altmetric
CASE SERIES

Neuroleptic Malignant Syndrome Improved with Intramuscular Administration of the Anticholinergic Agent, Biperiden

Koichi Nisijima1 Department of Psychiatry, Nasukougen Hospital, Nasu-machi, Tochigi, Japan;2 Department of Psychiatry, Jichi Medical University, Shimotuke City, Tochigi, JapanCorrespondence[email protected]
View further author information
Pages 281-286 | Received 30 Mar 2023, Accepted 06 May 2023, Published online: 12 May 2023

References

  • Guinart D, Misawa F, Rubio JM, et al. A systematic review and pooled, patient-level analysis of predictors of mortality in neuroleptic malignant syndrome. Acta Psychiatr Scand. 2021;144(4):329–341. doi:10.1111/acps.13359
  • Strawn JR, Keck PE, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry. 2007;164(6):870–876. doi:10.1176/ajp.2007.164.6.870
  • Strenbach H. The serotonin syndrome. Am J Psychiatry. 1991;148(6):705–713.
  • Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1):185–202. doi:10.1016/S0025-7125(16)30278-4
  • American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, District of Columbia: American Psychiatric Association; 1994.
  • Woodbury MM, Woodbury MA. Neuroleptic-induced catatonia as a stage in the progression toward neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry. 1992;31(6):1161–1164. doi:10.1097/00004583-199211000-00028
  • Amore M, Zazzeri N. Neuroleptic malignant syndrome after neuroleptic discontinuation. Prog Neuropsychopharmacol Biol Psychiatry. 1995;19(8):1323–1334. doi:10.1016/0278-5846(95)00269-3
  • Turner MR, Gainsborough N. Neuroleptic malignant-like syndrome after abrupt withdrawal of Baclofen. J Psychopharmacol. 2001;15(1):61–63. doi:10.1177/026988110101500111
  • Nielsen J, Bruhn AM. Atypical neuroleptic malignant syndrome caused by olanzapine. Acta Psychiatr Scand. 2005;112(3):238–240. doi:10.1111/j.1600-0447.2005.00578.x
  • Nisijima K, Shioda K. A rare case of neuroleptic malignant syndrome without elevated serum creatine kinase. Neuropsychiatr Dis Treat. 2014;10:403–407. doi:10.2147/NDT.S58677
  • Caroff SN, Roberts CB, Rosenberg H, et al. Intravenous dantrolene in hypermetabolic syndromes: a survey of the U.S. Veterans Health Administration database. BMC Anesthesiol. 2022;22(1):298. doi:10.1186/s12871-022-01841-z
  • Brocks DR. Anticholinergic drugs used in Parkinson’s disease: an overlooked class of drugs from a pharmacokinetic perspective. J Pharm Pharmaceut Sci. 1999;2(2):39–46.
  • Deuschl G, Oepen G, Hermle L, Kindt H. Neuroleptic malignant syndrome: observations on altered consciousness. Pharmacopsychiatry. 1987;20(4):168–170. doi:10.1055/s-2007-1017097
  • Schvehla TJ, Herjanic M. Neuroleptic malignant syndrome, bromocriptine, and anticholinergic drugs. J Clin Psychiatry. 1988;49(7):283–284.
  • Gratz SS, Levinson DF, Simpson GM. The treatment and management of neuroleptic malignant syndrome. Prog Neuropsychopharmacol Biol Psychiatry. 1992;16(4):425–443. doi:10.1016/0278-5846(92)90051-F
  • Spivak B, Gonen N, Mester R, Averbuch E, Adlesberg S, Weizman A. Neuroleptic malignant syndrome associated with abrupt withdrawal of anticholinergic agents. Int Clin Psychopharmacol. 1996;11(3):207–209. doi:10.1097/00004850-199609000-00009
  • Hasan MY, Schauben JL, Holmes CH. Management of neuroleptic malignant syndrome with anticholinergic medication. Vet Hum Toxicol. 1999;41(2):79–81.
  • Dhib-Jalbut S, Hesselbrock R, Mouradian MM, Means ED. Bromocriptine treatment of neuroleptic malignant syndrome. J Clin Psychiatry. 1987;48(2):69–73.
  • Davis JM, Caroff SN, Mann SC. Treatment of neuroleptic malignant syndrome. Psychiatr Ann. 2000;30:325–331. doi:10.3928/0048-5713-20000501-10
  • Ware MR, Feller DB, Hall KL. Neuroleptic malignant syndrome: diagnosis and management. Prim Care Companion CNS Disord. 2018;20(1):17r02185. doi:10.4088/PCC.17r02185
  • van Rensburg R, Decloedt EH. An approach to the pharmacotherapy of neuroleptic malignant syndrome. Psychopharmacol Bull. 2019;49(1):84–91. doi:10.1016/j.genhosppsych.2010.11.013
  • Kuhlwilm L, Schönfeldt-Lecuona C, Gahr M, et al. The neuroleptic malignant syndrome-a systematic case series analysis focusing on therapy regimes and outcome. Acta Psychiatr Scand. 2020;142(3):233–241. doi:10.1111/acps.13215
  • Serdenes R, Orr S, Trio P, Chandrasekhara S, Musselman M. A rare case report of a corpus callosal splenial lesion in the context of atypical Neuroleptic malignant syndrome. J Investig Med High Impact Case Rep. 2021;9:23247096211029751.
  • Mogollon Díaz JP, Lizcano Toloza LY, Serrano García AY, et al. Neuroleptic malignant syndrome associated with atypical antipsychotics: a case report. Rev Colomb Psiquiatr. 2021;52(1):78–81.
  • Coons DJ, Hillman FJ, Marshall RW. Treatment of neuroleptic malignant syndrome with dantrolene sodium: a case report. Am J Psychiatry. 1982;139(7):944–945.
  • Guerrero RM, Shifrar KA. Diagnosis and treatment of neuroleptic malignant syndrome. Cin Pharm. 1988;7(9):697–701.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.